Beneke T, Madden R, Makin L, Valli J, Sunter J and Gluenz E. A CRISPR Cas9 highthroughput genome editing toolkit for kinetoplastids. Royal Society Open Science, 2017. ESM File 1: Supplementary Tables, Figures and Methods

Supplementary Tables

Table S1. List of pPLOT plasmids

Name	Resistance	5' tagging cassette		3' tagging cassette	
		tags	size	tags	size
			(kb)		(kb)
pPLOT-mNG	BLAST	Myc ₍₃₎ ::mNeonGreen	2.1	mNeonGreen::Myc ₍₃₎	2.5
blast-blast					
pPLOT-mNG	NEO	Myc ₍₃₎ ::mNeonGreen	2.5	mNeonGreen::Myc ₍₃₎	2.9
neo-neo					
pPLOT- mNG	PURO	Myc ₍₃₎ ::mNeonGreen	2.3	mNeonGreen::Myc ₍₃₎	2.7
puro-puro					
pPLOT-	BLE	Myc ₍₃₎ ::mCherry	2.1	mCherry::Myc ₍₃₎	2.5
mCherry-					
phleo-phleo					
pPLOT-	PURO	Myc ₍₃₎ ::mCherry	2.3	mCherry::Myc ₍₃₎	2.7
mCherry-					
puro-puro					
pPLOT -Halo -	BLE	Myc ₍₃₎ ::Ty::Halo::Ty	2.3	Ty::Halo::Ty::Myc ₍₃₎	2.7
phleo-phleo					
pPLOT -Halo -	PURO	Myc ₍₃₎ ::Ty::Halo::Ty	2.4	Ty::Halo::Ty::Myc ₍₃₎	2.8
puro-puro					
pPLOT-10 Ty -	PURO	Myc ₍₃₎ ::Ty ₍₁₀₎	2.0	Ty ₍₁₀₎ ::Myc ₍₃₎	2.3
puro-puro					
pPLOT-	PURO	Myc ₍₃₎ ::Luciferase	2.1	Luciferase::Myc ₍₃₎	2.5
nanoLuc-					
puro-puro					
pPLOT-	BLE	Myc ₍₃₎ ::Luciferase	1.9	Luciferase::Myc ₍₃₎	2.3
nanoLuc-					
phleo-phleo					
pPLOT- BirA*-	PURO	Myc ₍₃₎ ::BirA*	2.6	BirA*::Myc ₍₃₎	3.0
puro-puro					
pPLOT- BirA*-	BLE	Myc ₍₃₎ ::BirA*	2.4	BirA*::Myc ₍₃₎	2.8
phleo-phleo					

Table S2. List of pT plasmids

Name	Resistance	knockout cassette size (kb)
pTBlast	BLAST	1.7
pTNeo	NEO	1.75
pTPuro	PURO	1.8

Table S3. List of expression plasmids for Cas9, T7 RNAP, and addback

Name	Resistance	protein expression	targeting sequences	species
pRM006	HYG	hSpCas9	β-tubulin array	L. major
рТВ007	HYG	hSpCas9, T7 RNAP	β-tubulin array	L. major
рТВ008	PHLEO	T7 RNAP	SSU rRNA	Leishmania spp.
рТВ011	PURO BLAST	hSpCas9	β-tubulin array	T. brucei
pTadd	PHLEO	(experiment- specific)	β-tubulin array	L. major



Fig. S1



pPLOT Blast-mNeonGreen-Blast





Fig. S4



Fig. S5



Fig. S6











Fig. S8

Figure Legends

Figure S1. Expression of Cas9 and T7 RNAP

(A) Upper panel: Whole cell lysates of *L. mexicana* wild type (WT), the uncloned *L. mex* Cas9 population (P) and five clonal *L. mex* Cas9 cell lines (A2, B11, E8, G2 and G7) were analysed in a Western blot probed with anti-FLAG. The calculated MW for hSpCas9 is 165kDa. C, positive control containing a 41 kDa protein with a FLAG epitope (Abcam, ab5395). Lower panel: the membrane stained with Ponceau S before antibody detection. (B) histogram showing cell volumes of *L. mexicana* wild type cells and *L. mex* Cas9 clone G2 measured using a CASY cell counter. (C, D) Growth curves of *L. mexicana* wild type, *L. mex* Cas9 clone G2, *L. mex* Cas9 T7 clones c2 and c5. Cultures were seeded at $1x10^6$ cells/ml and cells were counted and diluted back to $1x10^6$ cells/ml every 24 h (C) or left to grow to stationary phase (D).

Figure S2. Detection of Cas9 and T7 RNAP in Western blots of *Leishmania* spp. and *T. brucei* cell lines

Western blot of whole cell lysates probed with anti-Flag (upper-panel) or anti-T7 RNAP (lower-panel). The asterisk (*) indicates the *L. mex* Cas9 T7 cell line. The Ponceau S-stained membrane for each blot, showing the tubulin band, is included as a loading control.

Figure S3. Detailed maps of pPLOT and pT

Maps of pT and pPLOT plasmids. Dotted lines indicate site where they were linearized for display purposes. The 5' and 3' UTRs flanking the drug resistance genes in pTBlast, pTPuro and pTNeo are labelled with LmxM GeneIDs indicating the origin of the UTR sequences.

Figure S4. Detection of pPLOT tags on Western blot

The *L. mexicana PF16* gene was tagged in its endogenous locus with pPLOT amplicons encoding different tags; for each tag two cell lines were produced, to generate N- or C-

terminal fusions. Upper panel: Western blot of whole cell lysates tagged with an anti-myc antibody. Lower panel: the membrane stained with Ponceau S before antibody detection. Tagged nLuc runs slightly faster than its calculated MW.

Figure S5. sgRNA target counts for automated primer design

Each selected sgRNA target (including the PAM site) was aligned to the relevant genome and the number of matches was counted. The histogram shows frequencies for counted numbers of matches; the majority of sgRNAs match a unique site in the genome.

Figure S6. Sequence of edited *PF16* locus

(A) 5' end of the *PF16* gene sequence. The location of the 5'HF, 20 nt gRNA target and cleavage site are indicated. Red numbers indicate nucleotide positions relative to the start codon and red letters denote the start codon. PAM, protospacer adjacent motif. (B, C) Sequence alignment of the annotated *PF16* sequence and expected sequence resulting from integration of the pT drug resistance cassettes pTNeo (B) or pTPuro (C) and sequencing reads obtained from the $\Delta PF16$ population and a $\Delta PF16$ clone; green and orange boxes show the sequencing chromatograms.

Figure S7. Tagging and knockout of *PF16* in *L. major*

(A) Diagram showing *hSpCas9* and *T7 RNAP* integrated in the β -tubulin locus (β -TUB) of *L. major*. (B) Growth curve of *L. major* wild type (WT) and *L. major* pTB007. (C) Micrograph showing flagellar localisation of PF16::mNG in *L. major* pTB007 co-transfected with a tagging cassette amplified from pPLOT and *PF16* sgRNA template. Phase contrast image merged with mNG fluorescence (green) and Hoechst-stained DNA fluorescence (cyan). Scale bar 5 μ m. (D) PCR analysis of the *L. major* pTB007 Δ *PF16* cell line. Left panel: PCR products visualised on agarose gel. M, 100 bp DNA ladder; P, parental cell line *L. major* pTB007; KO, Δ *PF16* population. Right panel: diagram showing the *PF16* locus and PCR primers (arrows)

used to test for presence of the CDS or correct integration of drug resistance genes (blue boxes).

Figure S8. T. brucei cell lines expressing Cas9 and T7 RNAP

(A) Diagram showing location of *T7 RNAP* upstream of the tubulin (*TUB*) array in *T. brucei* SmOx cell lines (adapted from Poon *et al.*, 2012. *Open Biology.* **2**, 110037; *TET R* denotes Tetracyclin repressor protein gene) and pTB011 integrated in the tubulin locus for expression of hSpCas9. (B, C) Growth curves of procyclic form *T. brucei* SmOx P9, bloodstream form SmOx B4 and their pTB011-transfected derivatives. (D) Strategy for donor DNA amplification from pPOTv4 plasmids (Dean *et al.*, 2015. *Open Biology.* **5**, 140197). primer pairs 1/2 and 4/5 amplify N- and C-terminal tagging cassettes, respectively; primer pair 1/7 amplifies knockout cassettes. Primers include 30 nt HF for double-strand break repair by homologous recombination. Primers 3 and 6 (not shown) are used to amplify the 5' and 3' sgRNA templates.

Supplementary methods

Antibodies and buffers used in Western blots

Antibody	Blocking	1 st Ab	Wash buffer	2 ⁿ Ab buffer
	buffer	dilution		
Anti-T7 RNAP,	TBST* + 1%	1:2,500 in	TBST	Anti-mouse
Novagen 70566	gelatin	TBST		1:20,000
				TBST + 1%
				milk (Marvel)
Anti-myc,	TBST + 5%	1:3,000 in	TBST + 5%	Anti-mouse
Millipore 05-724	milk (Marvel)	TBST + 5%	milk (Marvel)	1:20,000
		milk (Marvel)		TBST + 5%
				milk (Marvel)
Anti-FLAG M2,	TBST + 5%	1:25,000 in	TBST + 5%	Anti-mouse
Sigma F3165	milk (Marvel)	TBST + 5%	milk (Marvel)	1:20,000
		milk (Marvel)		TBST + 5%
				milk (Marvel)
Anti-LPG, LT22	TBST + 5%	1:1,000 in	TBST	Anti-mouse
[1]	milk (Marvel)	TBST + 5%		1:20,000
		milk (Marvel)		TBST + 5%
				milk (Marvel)
Anti-GPI-PLC	TBST + 5%	1:1,500 in	TBST + 5%	Anti-rabbit
[2]	milk (Marvel)	TBST + 5%	milk (Marvel)	1:5,000 in
		milk (Marvel)		TBST + 5%
				milk (Marvel)

*TBST: Tris-buffered saline with 0.05% Tween 20

1. Ilg T, Harbecke D, Wiese M, Overath P (1993) Eur J Biochem 217: 603-615.

2. Sunter J, Webb H, Carrington M (2013) PLoS Pathog 9: e1003566.

PCR Primers

All sequences are written in the 5' to 3' orientation. Underlined sequences indicate sgRNA target sites.

sgRNA transcription

sgRNA forward (n, gene-sepcific target sequence)	GAAATTAATACGACTCACTATAGGnnnnnnnnnnnnnnnn
G00	AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATT TCTAGCTCTAAAAC

Recombination rate measurement

PF16 3' sgRNA	GAAATTAATACGACTCACTATAGG <u>TGCAGCAGCACTAGCGGGGGGGGG</u> GTTTTAGAGCTAGAAAT
forward	AGC

mCherry / eYFP double tagging of PF16

PF16 eYFP	333: AAGATCGAGAACTACCACGTGCAGCAGCACGTGAGCAAGGGCGAGGAGCTGTT	
forward		
PF16 eYFP	224: COACCETECATECCETECCEAAATTACCCCTCCCACACATAACCACAC	
reverse		
PF16 mCherry		
forward		
PF16 mCherry		
reverse		
PF16 sgRNA	295:	
forward	GAAATTAATACGACTCACTATAGG <u>CGGATGCTCAGCGGGCCTTT</u> GTTTTAGAGCTAGAAATAGC	

Construction of pT plasmids

	5'UTR,	3'UTR,	Nested primers,
	1 st reaction	1 st reaction	2 nd second reaction
pTBlast	478F: TTAGCAATCTGAGCAATCTGCCGGA TGAAAACGAGAGAGAGAGAC	480F: CTCTGGTTATGTGTGGGAGGG CTAAATAGAAGCCACACCGCG TGAG	482F: GTCGCAATTTAAATGTATAATGCAG ACCTGCTGCCGGATGAAAACGAGA GAGAGAC
	479R: GGGTGGATTCTTCTTGAGACAAAGG CATGGTGGAGCGAGGATACGAG	481R: TCTTAGTACGAACTGCAATGCA ACCAGTGTGTCAGTTGGAGAG A	483R: CGAGTCATTTAAATCCAATTTGAGA GACCTGTGCAACCAGTGTGTCAGT TGGAGAGA
TNeo	502F: TTAGCAATCTGAGCAATCTGCTGAC CTACGCAGCCTTTTGCG	504F: CTATCGCCTTCTTGACGAGTTC TTCTGAAGCTCCGCCGGTGTT CGTC	506F: GTCGCAATTTAAATGTATAATGCAG ACCTGCTGCTGACCTACGCAGCCT TTTGCG
G	503R: TCCATCTTGTTCAATGGCCGATCCC ATAGCCTTCGAGTATGAGCTGCTTT	505R: TCTTAGTACGAACTGCAATGCA GATGAGAAAGCGCGGCCATC	507R: CGAGTCATTTAAATCCAATTTGAGA GACCTGTGCAGATGAGAAAGCGC

			GGCCATC
uro	496F: TTAGCAATCTGAGCAATCTGCAGCC GTTGCATTGGTGGTCGT	498F: CATGACACGTAAGCCGGGAGC CTAAGTCGAGCGCTCACCTCT GAA	500F: GTCGCAATTTAAATGTATAATGCAG ACCTGCTGCAGCCGTTGCATTGGT GGTCGT
рТF	497R: GACGAACCGTTGGCTTGTATTCAGT CATTATGAAAGACCGCAAAAGAAAA TGTG	499R: TCTTAGTACGAACTGCAATGCG TCGTTGTAGTTCATGGAGACAC	501R: CGAGTCATTTAAATCCAATTTGAGA GACCTGTGCGTCGTTGTAGTTCAT GGAGACAC

Construction of pPLOT plasmids

5'PGKB myc-tag forward	473: TTAGCAAAGCTTAGAACCGGAACCGGAACCACTACCAGAACCCAGGTCCTCCTCGCTAATCAGC TTCTGCTCGAGGTCCTCCTCGCTAATGA
5'PGKB myc-tag reverse	474: AACTATCTTCCACTTGTCAAGCATGGAACAGAAGCTGATCAGCGAAGAAGACCTGGAGCAAAAG CTCATTAGCGAGGAGGACCTCGAGCA
5'PGKB second reaction	472: TTAGCAACGCGTTCGAGACCGACAAGACCAGAAT
PGKB/A myc-tag forward	475: TTAGCAGGATCCGGATCAGGATCTGGATCAGGATCGGGTAGTGAACAGAAGCTGATCAGCGAAG AAGACCTGGAGCAAAAGCT
PGKB/A myc-tag reverse	476: GAATTCTCAGTGGTGGTGGTGGTTACAGGTCCTCCTCGCTAATCAGCTTCTGCTCGAGGTCCTC CTCGCTAATGAGCTTTTGCTCCAGGTCTTCTTCGC
PGKB/A second reaction	477: TTAGCAGCTAGCCGCTTGACAAGTGGAAGATAGTTG

Construction of addback plasmids

PF16 forward	533ABF: GCAATCACTAGTCAAACAAAGCATGTCGAATCGGG
PF16 reverse	533ABR: GTCGCAGAATTCCCTCCTCCCCCGCTAGTGCTGCT
LPG1 forward	LPG_350: TTACGTACTAGTCACAGAGAAATGGCGCCG
LPG1 reverse	LPG_351: TTACGTCCTCGAGBAGAATGCTTAACGGGAGCGA

Tagging and knockout of PF16 and LPG1 with pT / pPLOT plasmids in *L. mexicana*

<i>Lmex</i> PF16 5'HF forward	533NF: TACAACGCACACGGGGACACGTATCCGCGCgtataatgcagacctgctgc
<i>Lmex</i> PF16 5'HF reverse	533NR: GAAGGTTTGCAGAATAACCCGATTCGACATactacccgatcctgatccag
<i>Lmex</i> PF16 3'HF forward	533CF: AAGATCGAGAACTACCACGTGCAGCAGCACggttctggtagtggttccgg
<i>Lmex</i> PF16 3'HF reverse	533CR: CGCGACGAGCAGCGTGCATGGGCGTGACTGccaatttgagagacctgtgc
<i>Lmex</i> PF16 5' sgRNA forward	GAAATTAATACGACTCACTATAGG <u>CTTTGTTTGGCGGACGGGAG</u> GTTTTAGAGCTAGAAATAGC
Lmex PF16 3'	GAAATTAATACGACTCACTATAGG <u>CGGATGCTCAGCGGGCCTTT</u> GTTTTAGAGCTAGAAATAGC

sgRNA		
forward		
LPG1 5'HF		
forward		
LPG1 3'HF		
reverse		
LPG1 5'		
sgRNA	GAAATTAATACGACTCACTATAGG <u>TGTTTCTACGAGGAGGCACTGGG</u> GTTTTAGAGCTAGAAATAGC	
forward		
LPG1 3'		
sgRNA	GAAATTAATACGACTCACTATAGG <u>GGGAGCGTGTGCGGCGCATCAGG</u> GTTTTAGAGCTAGAAATAGC	
forward		

Tagging and knockout of PF16 with pT / pPLOT plasmids in *L. major*

<i>LmjF</i> PF16 5'HF	587NF: CGTATCAGCGCTACACAGTGGCCCTCTCCTgtataatgcagacctgctgc	
forward		
<i>LmjF</i> PF16 5'HF		
reverse	Some and the address and the addre	
<i>LmjF</i> PF16 3'HF	587CF: AAGATCGAGAACTACCACGTGCAGCAGCACggttctggtagtggttccgg	
forward		
<i>LmjF</i> PF16 3'HF	587CR: CGAGCAGCGTGCGTGGGCGTGACTATGCCGccaatttgagagacctgtgc	
reverse		
<i>LmjF</i> PF16 5'		
sgRNA forward		
<i>LmjF</i> PF16 3'		
sgRNA forward		

Tagging and knockout of GPI-PLC

GPI-PLC 5'HF forward	593NF: AAAGAAAGAAAGAAAGAAAGAAAAGAAAAGGTATAATGCAGACCTGCTGC	
GPI-PLC PF16	593NR: CTGCGGTGACCACTTTACACCACCAAACATACTACCCGATCCTGATCCAG	
5'HF reverse		
GPI-PLC PF16		
3'HF forward		
GPI-PLC PF16		
3'HF reverse for	593CR: CACTTAACTTTTTTTTTTTTTTTAAACCCTCCAATTTGAGAGACCTGTGC	
tagging		
GPI-PLC PF16		
3'HF reverse for	593CRF: CACTTAACTTTTTTTTTTTTTTTTAAACCCTCCGGAACCACTACCAGAACC	
knockout		
GPI-PLC PF16 5'		
sgRNA forward		
GPI-PLC PF16 3'		
sgRNA forward		

Knockout validation

ORF amplification	Lmex PF16 ORF forward	533OF: CCTTCGACGAGTACCAGAAGGCA

	Lmex PF16 ORF reverse	533OR: CATCTCCAGACACGACGTTCTCG	
	LmajF PF16 ORF forward	587OF: GACGAGTACCAGAAGGCACG	
	LmajF PF16 ORF reverse	587OR: CATCTCCAGAAACGACGTTC	
	LPG1 ORF forward	LPG_334: ATTAGTGCGTATCGGCCTGT	
	LPG1 ORF reverse	LPG_335: AATGACAGCGAATATTCTCGC	
	GPI-PLC forward	593OF: TCATGGATGAGTGACACGCG	
	GPI-PLC reverse	593OR: AAAGATTTTGACAACGTCCC	
	Lmex PF16 5'UTR		
Amplification of sequence across	forward		
integration junction, Lmex PF16	Neomycin reverse	519: GTCTTGACAAAAAGAACCGGGC	
	Puromycin reverse	558: TCAATGTGTCGATCTGGGTCAAC	
Amplification of sequence across	LPG1 3'UTR reverse	LPG_331: TTGATTCGGTGATGGCTCG	
integration junction 1 PG1	Blasticidin forward	LPG_127: CTGCATCCTGGGATCAAAGC	
	Neomycin forward	LPG_319: ACCGCTTCCTCGTGCTTTA	
	<i>LmajF</i> PF16 5'UTR		
Amplification of sequence across	forward		
integration junction, <i>LmajF</i> PF16	Blastacidin reverse	518A: CCGTTGCTCTTTCAATGAGGGTG	
	Puromycin reverse	558: TCAATGTGTCGATCTGGGTCAAC	
Amplification of sequence across	GPI-PLC 5'UTR forward	593UF: GTCGTCGTAGTTGTTGTTAT	
integration junction GPI-PLC	Neomycin reverse	519: GTCTTGACAAAAAGAACCGGGC	
	Hygromycin reverse	JV78: CAGCTATTTACCCGCAGGAC	
Sequencing primers for analysis of	Neomycin integration	532: CTGTTCCTGTCGTACGAAAG	
Lmex PF16 knockout cell line	Puromycin integration	533UF: GACGTCGCTGCAGAAGTTATCCT	

Detection of sgRNA template

G00F	562: TTAATACGACTCACTATAGG
G00R	563: GCACCGACTCGGTGCCACTT